Eribulin in the treatment of advanced breast cancer: Real-world scenario from 39 Italian centers - ESEMPiO study

Sandro Barni; Luca Livraghi; Maria Morritti; Patrizia Vici; Andrea Michelotti; Saverio Cinieri; Caterina Fontanella; Luca Porcu; Lucia Del Mastro; Fabio Puglisi

doi:10.2217/fon-2018-0324

Eribulin in the treatment of advanced breast cancer: Real-world scenario from 39 Italian centers - ESEMPiO study

Sandro Barni, Luca Livraghi, Maria Morritti, Patrizia Vici, Andrea Michelotti, Saverio Cinieri, Caterina Fontanella, Luca Porcu, Lucia Del Mastro, Fabio Puglisi

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world. Patients & methods: Baseline characteristics, treatment administration and safety were summarized using descriptive statistics. Results: No safety concerns were raised in the population enrolled in the ESEMPiO database and treated in a real-life practice. Median progression-free survival and overall survival were 3.2 and 10.1 months, respectively. EM activity was similar between breast cancer subtypes. Conclusion: In metastatic breast cancer patients treated with EM in 'real-world' setting, the clinician-registered outcomes were comparable to those reported in pivotal trials. Furthermore, EM maintained clinical activity and a tolerable safety profile.

Original language	English
Pages (from-to)	33-44
Number of pages	12
Journal	Future Oncology
Volume	15
Issue number	1
DOIs	https://doi.org/10.2217/fon-2018-0324
Publication status	Published - Jan 1 2019

Keywords

database
eribulin mesylate
metastatic breast cancer
real-world
safety

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2018-0324

Fingerprint Dive into the research topics of 'Eribulin in the treatment of advanced breast cancer: Real-world scenario from 39 Italian centers - ESEMPiO study'. Together they form a unique fingerprint.

Cite this

Eribulin in the treatment of advanced breast cancer : Real-world scenario from 39 Italian centers - ESEMPiO study. / Barni, Sandro; Livraghi, Luca; Morritti, Maria ; Vici, Patrizia; Michelotti, Andrea; Cinieri, Saverio; Fontanella, Caterina; Porcu, Luca; Del Mastro, Lucia ; Puglisi, Fabio.

In: Future Oncology, Vol. 15, No. 1, 01.01.2019, p. 33-44.

Research output: Contribution to journal › Article › peer-review

@article{f5df5f8f74c34a54a1e3902f5ef627fe,

title = "Eribulin in the treatment of advanced breast cancer: Real-world scenario from 39 Italian centers - ESEMPiO study",

abstract = "Aim: We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world. Patients & methods: Baseline characteristics, treatment administration and safety were summarized using descriptive statistics. Results: No safety concerns were raised in the population enrolled in the ESEMPiO database and treated in a real-life practice. Median progression-free survival and overall survival were 3.2 and 10.1 months, respectively. EM activity was similar between breast cancer subtypes. Conclusion: In metastatic breast cancer patients treated with EM in 'real-world' setting, the clinician-registered outcomes were comparable to those reported in pivotal trials. Furthermore, EM maintained clinical activity and a tolerable safety profile.",

keywords = "database, eribulin mesylate, metastatic breast cancer, real-world, safety",

author = "Sandro Barni and Luca Livraghi and Maria Morritti and Patrizia Vici and Andrea Michelotti and Saverio Cinieri and Caterina Fontanella and Luca Porcu and {Del Mastro}, Lucia and Fabio Puglisi",

year = "2019",

month = jan,

day = "1",

doi = "10.2217/fon-2018-0324",

language = "English",

volume = "15",

pages = "33--44",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "1",

}

TY - JOUR

T1 - Eribulin in the treatment of advanced breast cancer

T2 - Real-world scenario from 39 Italian centers - ESEMPiO study

AU - Barni, Sandro

AU - Livraghi, Luca

AU - Morritti, Maria

AU - Vici, Patrizia

AU - Michelotti, Andrea

AU - Cinieri, Saverio

AU - Fontanella, Caterina

AU - Porcu, Luca

AU - Del Mastro, Lucia

AU - Puglisi, Fabio

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aim: We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world. Patients & methods: Baseline characteristics, treatment administration and safety were summarized using descriptive statistics. Results: No safety concerns were raised in the population enrolled in the ESEMPiO database and treated in a real-life practice. Median progression-free survival and overall survival were 3.2 and 10.1 months, respectively. EM activity was similar between breast cancer subtypes. Conclusion: In metastatic breast cancer patients treated with EM in 'real-world' setting, the clinician-registered outcomes were comparable to those reported in pivotal trials. Furthermore, EM maintained clinical activity and a tolerable safety profile.

AB - Aim: We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world. Patients & methods: Baseline characteristics, treatment administration and safety were summarized using descriptive statistics. Results: No safety concerns were raised in the population enrolled in the ESEMPiO database and treated in a real-life practice. Median progression-free survival and overall survival were 3.2 and 10.1 months, respectively. EM activity was similar between breast cancer subtypes. Conclusion: In metastatic breast cancer patients treated with EM in 'real-world' setting, the clinician-registered outcomes were comparable to those reported in pivotal trials. Furthermore, EM maintained clinical activity and a tolerable safety profile.

KW - database

KW - eribulin mesylate

KW - metastatic breast cancer

KW - real-world

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=85058484815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058484815&partnerID=8YFLogxK

U2 - 10.2217/fon-2018-0324

DO - 10.2217/fon-2018-0324

M3 - Article

AN - SCOPUS:85058484815

VL - 15

SP - 33

EP - 44

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 1

ER -